PIM1 and acute lymphoblastic leukemia: Notably, although JAK/STAT pathway mutations have been reported in about 30% of T-ALL patients8,10, none of the previous studies evaluating the efficacy of pan-PIM inhibitors in T-ALL have studied cellular models with JAK/STAT pathway mutations.